03 Sep, 2020 RNAi Roundtable: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis
On September 3, 2020, we hosted an online RNAi Roundtable to review progress with patisiran and vutrisiran, RNAi therapeutics in development for the treatment of transthyretin-mediated amyloidosis. Of note, we announced we have obtained clinical pharmacology data supporting the potential for a biannual subcutaneous dosing regimen option for vutrisiran, providing further product differentiation as a potential best-in-class agent, and discussed new clinical data presented at the European Society of Cardiology 2020 Congress providing further evidence that treatment with patisiran may lead to substantial reduction in cardiac amyloid burden in ATTR amyloidosis.
Senior Vice President, General Manager, TTR Program
Nitasha Sarswat, M.D.
Director, Infiltrative Cardiomyopathy Program, University of Chicago Hospital
John Vest, M.D.
Vice President, Clinical Research
Senior Director, Program Leader, Vutrisiran Program